Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003
Open accessThe DOI matches its Crossref record.
Abstract
Aims: To describe trends in utilization and prescribing of statins and other lipid lowering drugs across Europe from data in routine administrative databases. Methods: Observational study in EU member states and Norway. Comparison of annual utilization data for lipid lowering agents by class and drug from national administrative databases for reimbursement over the period 1997–2003, measured in DDDs per 1000 inhabitants/day. Prescribed daily doses (PDD) of statins obtained from a commercial database (IMS Health) for 2000 and 2003, and used to calculate numbers of ‘patient treatment days’ (PTD) in each country in each year. Analysis of PTD to explain increased utilization of statins. Results: Use of lipid lowering agents varied among countries (in 2003, highest in Ireland and Norway, and lowest in Italy), but increased in all countries studied (between 2000 and 2003 by 274% in Ireland and by 56% in France). This increase was entirely due to increases in statin use. Prescribed daily doses of statins increased in all countries for which data was available between 2000 and 2003, but still usually fell below the doses used in the major trials of statins. As a result, the numbers of PTDs increased to a lesser extent than suggested by utilization (e.g. by 192% in Ireland and by 35% in France). One‐third of the total rise in utilization was explained by increased PDD, and two‐thirds by an increase in numbers of PTDs. Statins dominated the markets in all countries, although fibrates remained strong in France and Belgium (approximately 25% of all lipid lowering agents) and to a lesser extent Germany (10%). Conclusions: Use of statins across Europe has increased hugely over the study period. Some of the increase in use is due to higher prescribed daily doses, but two‐thirds is due to increases in numbers of patient days of treatment, either due to more patients treated or less likely to better compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care
OECD (2015) · OECD Health Policy Studies · doi:10.1787/9789264233010-en · Cited by 1,359
Repositioning of the global epicentre of non-optimal cholesterol
NCD Risk Factor Collaboration (NCD-RisC), Taddei, C., Zhou, B., Bixby, H., Carrillo-Larco, R. M., Danaei, G., Jackson, R. T., Farzadfar, F., Sophiea, M. K., Di Cesare, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2338-1 · Cited by 298
Truthmann, J., Schienkiewitz, A., Busch, M. A., Mensink, G. B. M., Du, Y., Bosy-Westphal, A., Knopf, H., & Scheidt-Nave, C. (2016) · BMC Public Health · doi:10.1186/s12889-016-2826-2 · Cited by 27
Metadata
- Authors
- Walley, T., Folino‐Gallo, P., Stephens, P., Van Ganse, E., & EuroMedStat group
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-08
- Volume
- 60
- Issue
- 5
- Pages
- 543-551
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1985534800
- Cited by
- 187
- References
- 0
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02478.x
- The paper
- Walley, T., Folino‐Gallo, P., Stephens, P., Van Ganse, E., & EuroMedStat group. (2005). Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02478.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.